Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The OTCBB Garbage Dump -- Ignore unavailable to you. Want to Upgrade?

To: Wayne Rumball who wrote (522)	8/4/1999 8:55:00 AM
From: 2MAR$	Read Replies (3) \| Respond to of 2942

(BSNS WIRE) BioLogix Sells Assets to TheHealthChannel.com, Inc. BioLogix Sells Assets to TheHealthChannel.com, Inc. Business Editors/Health & Medical Writers NEWPORT BEACH, Calif.--(BW HealthWire)--August 4, 1999--BioLogix International, Ltd. (OTCBB:BGIX) is pleased to announce that it is finalizing an agreement to sell TheHealthChannel.com website and certain related technology to TheHealthChannel.com, Inc. (OTCBB: THCL formerly IVTX) formerly known as Innovative Tracking Solutions Corporation ("Innovative"). BioLogix is retaining all other assets currently owned by BioLogix. THCL is a Delaware corporation that is fully compliant with the reporting requirements of the Securities Exchange Act of 1934, as amended. Donald Shea, the ex-president of Clairol, Inc. is the President of THCL and Tom Lonergan, with over 25 years of hospital administration will continue in the position he held with BioLogix as THCL's COO, Secretary, and CFO. Both Mr. Shea and Mr. Lonergan were members of the BioLogix Board of Directors. All other existing Board members of BioLogix shall constitute THCL's Board until the next annual meeting of shareholders, with the exception of Mr. Michael Grandon. Mr. Grandon is no longer an officer or director of either BioLogix or THCL. Shareholders of record of BioLogix International, Ltd. as of the end of trading on August 4, 1999 are being offered the opportunity to exchange their BGIX shares for shares of THCL on a one-for-one basis. All free-trading shares of BGIX shall be exchanged for free-trading THCL shares and all restricted shares of BGIX shall be exchangeable into restricted THCL shares. BioLogix management recommends that all BGIX shareholders exchange their shares into THCL shares. All BioLogix shareholders of record as of August 4, 1999 shall receive a Letter of Transmittal containing instructions to complete the exchange of their shares; if the shares are held in DTC electronic format the broker of record shall receive the Letter of Transmittal. All shareholders shall have 15 days from the date of mailing to return their Letter of Transmittal. All questions regarding this process should be directed to the following e-mail address: tomlonergan@hotmail.com. BioLogix shareholders are also informed that BGIX will be delisted from the over-the-counter bulletin board system ("Bulletin Board") on approximately September 1, 1999. BioLogix retains its point-of-care blood analysis technology and related assets. The BioLogix Board is currently considering the eventual disposition of these assets. Certain shareholders of record of IVTX as of July 30, 1999 are being offered the opportunity to exchange their former IVTX shares for shares of THCL on a two IVTX shares-for-one THCL share. If you are an IVTX shareholder as of July 30, 1999 then please call 1-888-437-4343 in order to secure details regarding the exchange of your shares. Innovative is a Healthcare company that recently placed its operating assets into a privately owned company called Innovative Tracking Solutions, Inc. a Nevada corporation. It produces the Private Practice(TM) Vibration Reminder Disk and Patient Adherence Programs. TheHealthChannel.com, Inc. will feature Innovative's products on its web site. "We are excited about offering another value-added feature through our rapidly growing Internet portal," said Tom Lonergan. "While our focus is on helping the public to have more information and control over their own healthcare, Innovative's focus is on products and programs that help patients have more control over their treatment outcome. THCL's management believes that this creates a perfect fit." "We are pleased to find an acquiring company that enhances the marketplace exposure of our product line," said Dianna Cleveland, President and CEO of Innovative. "We look forward to working with TheHealthChannel.com over the next several months to reinforce the national exposure of our products." BioLogix paid $250,000 for the purchase of Innovative's management shares. Full details of the transaction will be filed with the SEC on a Form 8-K within 15 days. Please note: Included in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable; it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. --30--crd/sf* CONTACT: BioLogix International, Ltd. Tom Lon